RAPT RAPT Therapeutics Inc
Price (delayed)
$1.16
Market cap
$153.13M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.19
Enterprise value
-$12.12M
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
Highlights
RAPT's equity has surged by 99% since the previous quarter and by 29% year-on-year
The debt is down by 35% year-on-year and by 12% since the previous quarter
RAPT Therapeutics's quick ratio has decreased by 49% QoQ and by 34% YoY
The net income has contracted by 21% from the previous quarter and by 11% YoY
Key stats
What are the main financial stats of RAPT
Market
Valuations
Earnings
Shares outstanding
132.01M
Market cap
$153.13M
Enterprise value
-$12.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.21
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$136.1M
Net income
-$129.87M
EBIT
-$129.87M
EBITDA
-$126.33M
Free cash flow
-$83.42M
Per share
Balance sheet
Liquidity
EPS
-$3.19
EPS diluted
-$3.19
Free cash flow per share
-$2.05
Book value per share
$5.43
Revenue per share
$0
TBVPS
$5.9
Total assets
$240.33M
Total liabilities
$50.42M
Debt
$4.49M
Equity
$189.9M
Working capital
$186.89M
Debt to equity
0.02
Current ratio
4.87
Quick ratio
4.78
Net debt/EBITDA
1.31
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-82.2%
Return on equity
-98.9%
Return on invested capital
-193.3%
Return on capital employed
-67.6%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RAPT stock price
How has the RAPT Therapeutics stock price performed over time
Intraday
-0.85%
1 week
-20%
1 month
1.75%
1 year
-85.87%
YTD
-26.58%
QTD
-4.92%
Financial performance
How have RAPT Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$136.1M
Net income
-$129.87M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 21% from the previous quarter and by 11% YoY
RAPT's operating income is down by 19% QoQ and by 7% YoY
Growth
What is RAPT Therapeutics's growth rate over time
Valuation
What is RAPT Therapeutics stock price valuation
P/E
N/A
P/B
0.21
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
RAPT's EPS is down by 15% since the previous quarter and by 4.6% year-on-year
RAPT's equity has surged by 99% since the previous quarter and by 29% year-on-year
The P/B is 94% lower than the 5-year quarterly average of 3.7 and 80% lower than the last 4 quarters average of 1.1
Efficiency
How efficient is RAPT Therapeutics business performance
The ROIC has plunged by 146% YoY and by 59% from the previous quarter
The return on equity has dropped by 57% year-on-year and by 11% since the previous quarter
RAPT's ROA is down by 48% YoY and by 8% QoQ
Dividends
What is RAPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RAPT.
Financial health
How did RAPT Therapeutics financials performed over time
The total assets has soared by 122% from the previous quarter and by 39% YoY
RAPT Therapeutics's total liabilities has soared by 92% YoY
The debt is 98% smaller than the equity
RAPT's equity has surged by 99% since the previous quarter and by 29% year-on-year
RAPT Therapeutics's debt to equity has shrunk by 60% QoQ and by 60% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.